A randomized multicenter phase III study of taxane/carboplatin/cetuximab versus taxane/carboplatin as first-line treatment for patients with advanced/metastatic non-small cell lung cancer

Trial Profile

A randomized multicenter phase III study of taxane/carboplatin/cetuximab versus taxane/carboplatin as first-line treatment for patients with advanced/metastatic non-small cell lung cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 25 Jan 2010 Results published in the Journal of Clinical Oncology.
    • 06 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2008 Primary endpoint 'Survival' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top